{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:22:34Z","timestamp":1789636954839,"version":"4.0.0"},"reference-count":33,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T00:00:00Z","timestamp":1458518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0150749","type":"journal-article","created":{"date-parts":[[2016,3,21]],"date-time":"2016-03-21T17:33:33Z","timestamp":1458581613000},"page":"e0150749","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":55,"title":["Rituximab Effectiveness and Safety for Treating Primary Sj\u00f6gren\u2019s Syndrome (pSS): Systematic Review and Meta-Analysis"],"prefix":"10.1371","volume":"11","author":[{"given":"Francine Bertolais do Valle","family":"Souza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Jos\u00e9 Martiniano","family":"Porf\u00edrio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda Nazar\u00e9 Gomes","family":"Andriolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia Vajda de","family":"Albuquerque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Fernandes Mo\u00e7a","family":"Trevisani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2016,3,21]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1097\/00002281-199110000-00011","article-title":"New developments in Sj\u00f6gren's syndrome","volume":"3","author":"HM Moutsopoulos","year":"1991","journal-title":"Curr. Opin. Rheumatol"},{"issue":"1\u20132","key":"ref2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaut.2012.01.006","article-title":"Sjogren\u2019s syndrome: an update on clinical, basic and diagnostic therapeutic aspects","volume":"39","author":"AG Tzioufas","year":"2012","journal-title":"Autoimmun"},{"key":"ref3","first-page":"33","article-title":"Pathogenetic Aspects of Primary Sj\u00f6gren\u2019s Syndrome","author":"AG Tzioufas","year":"2012"},{"issue":"7","key":"ref4","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/ard.2003.014027","article-title":"Incidence of primary Sj\u00f6gren's syndrome in Slovenia","volume":"63","author":"M Plesivcnik Novljan","year":"2004","journal-title":"Ann. Rheum. Dis"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/rheumatology\/kei107","article-title":"Epidemiology of primary Sj\u00f6gren's syndrome in north-west Greece, 1982\u20132003","volume":"45","author":"Y Alamanos","year":"2006","journal-title":"Rheumatology. (Oxford)"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1001\/archinte.164.12.1275","article-title":"Clinical manifestations and early diagnosis of Sj\u00f6gren\u2019s syndrome","volume":"164","author":"SS Kassan","year":"2004","journal-title":"Arch. Intern. Med"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/0049-0172(73)90021-8","article-title":"Sj\u00f6gren's syndrome\u2014a clinical review","volume":"2","author":"AM Mason","year":"1973","journal-title":"1973; Seminars in arthritis and rheumatism"},{"key":"ref8","first-page":"401","article-title":"Immunological Tests in Primary Sj\u00f6gren Syndrome","author":"S Retamozo","year":"2012"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1001\/jama.2010.1014","article-title":"Treatment of Primary Sj\u00f6gren\u2019s syndrome: a systematic review","volume":"304","author":"M Ramos-Casals","year":"2010","journal-title":"JAMA"},{"issue":"5","key":"ref10","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.semarthrit.2007.06.002","article-title":"Primary Sj\u00f6gren's syndrome: current and prospective therapies","volume":"37","author":"A Thanou-Stavraki","year":"2008","journal-title":"Semin. Arthritis Rheum"},{"issue":"2","key":"ref11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1002\/art.22536","article-title":"Improvement of Sj\u00f6gren's syndrome after two infusions of rituximab (anti-CD20)","volume":"57","author":"V Devauchelle-Pensec","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"10","key":"ref12","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1517\/14712598.2011.605352","article-title":"Treatment of primary Sj\u00f6gren's syndrome with anti-CD20 therapy (rituximab). A feasible approach or just a starting point?","volume":"11","author":"PM Meiners","year":"2011","journal-title":"Expert. Opin. Biol. Ther"},{"issue":"6","key":"ref13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","article-title":"Classification criteria for Sj\u00f6gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group","volume":"61","author":"C Vitali","year":"2002","journal-title":"Ann. Rheum. Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1136\/ard.2009.110619","article-title":"EULAR Sj\u00f6gren\u2019s syndrome disease activity index: development of a consensus systemic disease activity index for primary Sj\u00f6gren\u2019s syndrome","volume":"69","author":"R Seror","year":"2010","journal-title":"Ann. Rheum. Dis"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1136\/ard.2010.143743","article-title":"EULAR Sj\u00f6gren\u2019s Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sj\u00f6gren\u2019s syndrome","volume":"70","author":"R Seror","year":"2011","journal-title":"Ann. Rheum. Dis"},{"key":"ref16","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"JPT Higgins","year":"2011"},{"key":"ref17","article-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"JJ Deeks","year":"2011"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1136\/ard.2007.083865","article-title":"Reduction of fatigue in Sj\u00f6gren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study","volume":"67","author":"S Dass","year":"2008","journal-title":"Ann. Rheum. Dis"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1002\/art.27314","article-title":"Effectiveness of Rituximab Treatment in Primary Sj\u00f6gren\u2019s Syndrome. A Randomized, Double-Blind, Placebo-Controlled Trial","volume":"62","author":"JM Meijer","year":"2010","journal-title":"Arthritis Rheum"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"233","DOI":"10.7326\/M13-1085","article-title":"Treatment of Primary Sj\u00f6gren Syndrome With Rituximab","volume":"160","author":"V Devauchelle-Pensec","year":"2014","journal-title":"Ann. Intern. Med"},{"issue":"suppl 10","key":"ref21","article-title":"Preliminary Results of a Double-Blind Randomised Trial of Rituximab Anti-B-Cell Therapy in Patients with Primary Sjogrens Syndrome [abstract]","volume":"67","author":"S Bowman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"ref22","doi-asserted-by":"crossref","first-page":"R172","DOI":"10.1186\/ar4359","article-title":"Efficacy and safety of rituximab treatment in early primary Sj\u00f6gren's syndrome: a prospective, multi-center,follow-up study","volume":"15","author":"F Carubbi","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.2014.7682","article-title":"Effects of hydroxychloroquine on symptomatic improvement in primary Sjogren syndrome: the JOQUER randomized clinical trial","volume":"312","author":"JE Gottenberg","year":"2014","journal-title":"JAMA"},{"issue":"5","key":"ref24","first-page":"896","article-title":"A double blind placebo controlled trial of azathioprine in the treatment of primary Sj\u00f6gren's syndrome","volume":"25","author":"EJ Price","year":"1998","journal-title":"J. Rheumatol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/15027732.1986.12461421","article-title":"Cyclosporin a therapy in patients with primary Sj\u00f6gren's syndrome: results at one year","volume":"61","author":"AA Drosos","year":"1986","journal-title":"Scand. J. Rheumatol. Suppl"},{"issue":"5","key":"ref26","first-page":"555","article-title":"Methotrexate in primary Sj\u00f6gren's syndrome","volume":"14","author":"FN Skopouli","year":"1996","journal-title":"Clin. Exp. Rheumatol"},{"issue":"8","key":"ref27","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1136\/ard.2006.060905","article-title":"Safety and efficacy of leflunomide in primary Sj\u00f6gren's syndrome: a phase II pilot study","volume":"66","author":"JM van Woerkom","year":"2007","journal-title":"Ann. Rheum. Dis"},{"issue":"20","key":"ref28","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1001\/archinte.165.20.2337","article-title":"The risk of lymphoma development in autoimmune diseases: a meta-analysis","volume":"165","author":"E Zintzaras","year":"2005","journal-title":"Arch. Intern. Med"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.0300-9475.2004.01432.x","article-title":"Circulating cytokines in primary Sjogren's syndrome determined by a multiplex cytokine array system","volume":"59","author":"P Szodoray","year":"2004","journal-title":"Scand. J. Immunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1136\/ard.62.2.168","article-title":"The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome","volume":"62","author":"X Mariette","year":"2003","journal-title":"Ann. Rheum. Dis"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1172\/JCI0214121","article-title":"Association of BAFF\/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome","volume":"109","author":"J Groom","year":"2002","journal-title":"J. Clin. Invest"},{"issue":"1","key":"ref32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/MD.0b013e31824125e4","article-title":"Prognosis and outcome of non-Hodgkin lymphoma in primary Sj\u00f6gren syndrome","volume":"91","author":"M Voulgarelis","year":"2012","journal-title":"Medicine"},{"issue":"3","key":"ref33","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/art.10221","article-title":"Long\u2010term risk of mortality and lymphoproliferative disease and predictive classification of primary Sj\u00f6gren's syndrome","volume":"46","author":"JP Ioannidis","year":"2002","journal-title":"Arthritis & Rheumatism"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0150749","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T21:39:53Z","timestamp":1748813993000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0150749"}},"subtitle":[],"editor":[{"given":"Silke","family":"Appel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2016,3,21]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2016,3,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0150749","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3,21]]}}}